Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 12/20 | 0.41 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088529 | 0.91 | FOXM1 (0.33) | ESRRAFOXM1SRD5A1NPC1RAB9A | |
| SCHEMBL10088901 | 0.89 | SRD5A1 (0.42) | ESRRAFOXM1SRD5A1SLC6A4MAOA | |
| SCHEMBL10088904 | 0.88 | SRD5A1 (0.37) | ESRRAFOXM1SRD5A1SLC6A4MAOA | |
| SCHEMBL10310541 | 0.82 | EPHX2 (0.36) | FOXM1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2326732 | 0.82 | SRD5A1 (0.42) | ESRRAFOXM1SRD5A1SLC6A4MAOA | |
| SCHEMBL10088463 | 0.80 | SRD5A1 (0.33) | SRD5A1NPC1RAB9AMAOAMAOB | |
| SCHEMBL10088465 | 0.79 | SRD5A1 (0.31) | SRD5A1NPC1RAB9A | |
| SCHEMBL10310548 | 0.78 | S1PR1 (0.44) | ESRRA | |
| SCHEMBL10088577 | 0.77 | SLC6A4 (0.34) | SLC6A4FFAR1FFAR4 | |
| SCHEMBL10088409 | 0.75 | ROR1 (0.37) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | ESRRA 645/4885FOXM1 693/4885SRD5A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.